149845-06-7 | Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, methanesulfonate (1:1)

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$7.00	$5.00
10mg	98%	in stock	$21.00	$15.00
25mg	98%	in stock	$35.00	$25.00
50mg	98%	in stock	$58.00	$41.00

Description

• Catalog Number: AA75033
• Chemical Name: Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, methanesulfonate (1:1)
• CAS Number: 149845-06-7
• Molecular Formula: C39H54N6O8S
• Molecular Weight: 766.9465
• MDL Number: MFCD00944907
• SMILES: CS(=O)(=O)O.NC(=O)C[C@@H](C(=O)N[C@H]([C@@H](CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2

Computed Properties

• Complexity: 1230
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 54
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 13

Literature

• Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems.

  Biochimica et biophysica acta 20140101

• GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

  Antimicrobial agents and chemotherapy 20131201

• Role of FAP48 in HIV-associated lipodystrophy.

  Journal of cellular biochemistry 20121101

• Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.

  Molecular pharmacology 20121001

• Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.

  Journal of pharmaceutical sciences 20120901

• Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.

  Medecine et maladies infectieuses 20120901

• Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.

  Oncology reports 20120801

• Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity.

  International journal of pharmaceutics 20120715

• Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.

  Antimicrobial agents and chemotherapy 20120701

• Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans.

  Canadian journal of microbiology 20120701

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Perspectives on addressing ionization matrix effects in LC-MS bioanalysis.

  Bioanalysis 20120601

• Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.

  AIDS (London, England) 20120515

• HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.

  AIDS (London, England) 20120515

• Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120501

• Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.

  Journal of clinical pharmacology 20120401

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• Resistance to TRAIL and how to surmount it.

  Immunologic research 20120401

• Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.

  Cell cycle (Georgetown, Tex.) 20120315

• Modulation of efflux proteins by electromagnetic field for delivering azidothymidine and saquinavir into the brain.

  Colloids and surfaces. B, Biointerfaces 20120301

• In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib.

  Oncology reports 20120301

• Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

  Protein science : a publication of the Protein Society 20120301

• High sodium butyrate levels induce MDR1 activation in colorectal cells: Impact of 15-deoxy-Δ(12,14)-prostaglandin J(2) on the resistance to saquinavir.

  Biochemical and biophysical research communications 20120224

• Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.

  Colloids and surfaces. B, Biointerfaces 20120201

• Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120101

• The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001.

  The Journal of pharmacy and pharmacology 20120101

• Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs.

  In vivo (Athens, Greece) 20120101

• Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study.

  PloS one 20120101

• Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field.

  Colloids and surfaces. B, Biointerfaces 20111201

• Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir.

  Colloids and surfaces. B, Biointerfaces 20111201

• Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.

  Therapeutic drug monitoring 20111201

• Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111120

• Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

  HIV medicine 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats.

  Basic & clinical pharmacology & toxicology 20111001

• Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid).

  International journal of pharmaceutics 20110915

• The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.

  Antiviral research 20110901

• Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir.

  Antiviral research 20110801

• Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.

  International journal of pharmaceutics 20110729

• Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells.

  Journal of cellular physiology 20110701

• A Janus molecule provides a rational reshape to a multi-functional drug.

  Cell cycle (Georgetown, Tex.) 20110301

• A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.

  Cell cycle (Georgetown, Tex.) 20110201

• Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases.

  International journal of cancer 20110101

• The anti-tumor effects of human immunodeficiency virus protease inhibitors: ready for real time?

  International journal of cancer 20110101

• Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions.

  Journal of medicinal food 20110101

• Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

  European journal of medical research 20110101

• Saquinavir: prolongation of PR and QT intervals.

  Prescrire international 20110101

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

  European journal of medical research 20110101

• Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

  Malaria journal 20110101

• Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies.

  Journal of microencapsulation 20110101

• [Evidence-based therapeutic drug monitoring for saquinavir].

  Therapie 20110101

• Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.

  Arzneimittel-Forschung 20110101

• Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.

  Antiviral therapy 20110101

• Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101223

• Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

  Experimental parasitology 20101201

• Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.

  Drug metabolism letters 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Nicotine and cotinine increases the brain penetration of saquinavir in rat.

  Journal of neurochemistry 20101201

• Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells.

  Neoplasia (New York, N.Y.) 20101201

• FDA notifications. New risk information added to label of antiviral saquinavir.

  AIDS alert 20101201

• Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101120

• HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.

  Mycoses 20101101

• Impact of drug transporters on cellular resistance towards saquinavir and darunavir.

  The Journal of antimicrobial chemotherapy 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.

  Biopharmaceutics & drug disposition 20101101

• Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity.

  Journal of neurochemistry 20101001

• Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.

  European journal of obstetrics, gynecology, and reproductive biology 20100901

• Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.

  Current HIV research 20100901

• Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.

  The FEBS journal 20100901

• Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes.

  The Journal of pharmacology and experimental therapeutics 20100701

• Enhancing the delivery of anti retroviral drug 'Saquinavir' across the blood brain barrier using nanoparticles.

  Current HIV research 20100701

• Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells.

  Journal of drug targeting 20100701

• Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.

  Biochemical and biophysical research communications 20100611

• Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).

  Journal of clinical pharmacology 20100401

• Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients.

  Infection 20100401

• Arrhythmia risk with saquinavir.

  AIDS patient care and STDs 20100401

• FDA notifications. Potential serious effect of combination saquinavir-ritonavir.

  AIDS alert 20100401

• Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.

  International journal of clinical pharmacology and therapeutics 20100301

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.

  Journal of medicinal chemistry 20100225

• Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein, Cyp3A4 enzymes, and microenvironments.

  The Journal of pharmacology and experimental therapeutics 20100201

• [The newest developments in anti-HIV-1 drugs].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun.

  Journal of acquired immune deficiency syndromes (1999) 20100101

• The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

  Antiviral therapy 20100101

• Immunomodulation in female B₆C₃F₁ mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage.

  Journal of immunotoxicology 20100101

• The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.

  Drug metabolism and pharmacokinetics 20100101

• Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir.

  Drug metabolism and pharmacokinetics 20100101

• Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

  European journal of medical research 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20091201

• Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

  Biological & pharmaceutical bulletin 20091201

• Drug repositioning using in silico compound profiling.

  Future medicinal chemistry 20091201

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

  Experimental parasitology 20091001

• Saquinavir, the pioneer antiretroviral protease inhibitor.

  Expert opinion on drug metabolism & toxicology 20091001

• Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.

  Pharmacotherapy 20091001

• Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice.

  Journal of pharmaceutical sciences 20090801

• The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090712

• Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.

  Addiction biology 20090701

• Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.

  AIDS (London, England) 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples.

  Journal of pharmaceutical and biomedical analysis 20090501

• Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.

  The Journal of antimicrobial chemotherapy 20090501

• The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.

  Molecular cancer therapeutics 20090501

• Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

  Journal of acquired immune deficiency syndromes (1999) 20090401

• HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.

  Experimental biology and medicine (Maywood, N.J.) 20090401

• A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.

  Rapid communications in mass spectrometry : RCM 20090401

• Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.

  The Journal of antimicrobial chemotherapy 20090301

• The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells.

  Gynecologic oncology 20090301

• Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.

  Toxicology in vitro : an international journal published in association with BIBRA 20090201

• The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.

  British journal of pharmacology 20090201

• Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles.

  International journal of pharmaceutics 20090105

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• Anti-HIV drugs for cancer therapeutics: back to the future?

  The Lancet. Oncology 20090101

• Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

  Antiviral therapy 20090101

• The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

  Antiviral therapy 20090101

• Preparation and performance evaluation of saquinavir laden cationic submicron emulsions.

  Drug delivery 20090101

• Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells.

  Biotechnology and bioengineering 20081201

• Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.

  European journal of clinical pharmacology 20081201

• A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20081201

• Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

  The Journal of antimicrobial chemotherapy 20081201

• P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate?

  The AAPS journal 20081201

• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  The Journal of infectious diseases 20081101

• Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.

  Current HIV research 20081101

• Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.

  British journal of pharmacology 20081101

• Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.

  International journal of pharmaceutics 20081001

• Maraviroc: in vitro assessment of drug-drug interaction potential.

  British journal of clinical pharmacology 20081001

• MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

  Experimental biology and medicine (Maywood, N.J.) 20080901

• Ultra-fast quantitation of saquinavir in human plasma by matrix-assisted laser desorption/ionization and selected reaction monitoring mode detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901

• Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

  Journal of molecular biology 20080801

• Roche Labs update insert for saquinavir.

  AIDS alert 20080801

• Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

  The Journal of antimicrobial chemotherapy 20080701

• Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

  The Pediatric infectious disease journal 20080701

• Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.

  Journal of acquired immune deficiency syndromes (1999) 20080701

• Invirase package insert updated.

  AIDS patient care and STDs 20080701

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.

  Clinical pharmacology and therapeutics 20080601

• Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

  The Journal of antimicrobial chemotherapy 20080601

• Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz.

  AIDS research and human retroviruses 20080601

• An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.

  Pharmaceutical research 20080501

• Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.

  Drug metabolism and disposition: the biological fate of chemicals 20080501

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  British journal of clinical pharmacology 20080401

• Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers.

  International journal of pharmaceutics 20080303

• Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases.

  Journal of the American Chemical Society 20080227

• Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.

  International journal of pharmaceutics 20080122

• Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.

  Bioorganic & medicinal chemistry 20080115

• The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations.

  Biomacromolecules 20080101

• Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20080101

• Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.

  BMC neuroscience 20080101

• Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta.

  Human & experimental toxicology 20080101

• Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.

  Acta poloniae pharmaceutica 20080101

• Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

  Antiviral therapy 20080101

• P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.

  Ethnicity & disease 20080101

• Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

  PloS one 20080101

• Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20080101

• Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

  Antiviral therapy 20080101

• Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.

  Therapeutic drug monitoring 20071201

• Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.

  Journal of molecular graphics & modelling 20071101

• Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

  Basic & clinical pharmacology & toxicology 20071101

• Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

  HIV medicine 20071101

• The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.

  Clinical pharmacology and therapeutics 20071001

• Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

  AIDS (London, England) 20070912

• Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products.

  Canadian journal of physiology and pharmacology 20070901

• Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals.

  Immunology letters 20070815

• Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.

  Clinical pharmacology and therapeutics 20070801

• Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.

  International journal of pharmaceutics 20070801

• Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.

  AIDS (London, England) 20070731

• Development and validation of a reversed-phase liquid chromatographic method with fluorescence detection for the study of Saquinavir pharmacokinetics in rat plasma.

  Analytica chimica acta 20070702

• Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.

  The Journal of antimicrobial chemotherapy 20070701

• Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601

• Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

  Antimicrobial agents and chemotherapy 20070601

• The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

  Therapeutic drug monitoring 20070601

• Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

  International journal of pharmaceutics 20070524

• CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.

  Clinical pharmacology and therapeutics 20070501

• Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

  The Journal of antimicrobial chemotherapy 20070501

• Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

  HIV medicine 20070501

• Multidrug resistance proteins affect drug transmission across the placenta.

  American journal of obstetrics and gynecology 20070501

• Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

  The Journal of infection 20070401

• Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070401

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.

  Journal of pharmacokinetics and pharmacodynamics 20070401

• Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.

  Proteins 20070401

• Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

  The Journal of antimicrobial chemotherapy 20070401

• Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

  Therapeutic drug monitoring 20070401

• Antimalarial activity of sera from subjects taking HIV protease inhibitors.

  AIDS (London, England) 20070330

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.

  British journal of clinical pharmacology 20070301

• Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

  The Journal of antimicrobial chemotherapy 20070301

• Evaluation of an International Pharmacopoeia method for the analysis of saquinavir (mesilate) bulk drugs by liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20070219

• Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.

  Journal of clinical pharmacology 20070201

• HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.

  AIDS research and human retroviruses 20070201

• Dose reduction effective in alleviating symptoms of saquinavir toxicity.

  International journal of STD & AIDS 20070201

• Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan.

  Journal of drug targeting 20070201

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis.

  International journal of antimicrobial agents 20070101

• Anti-HIV agents. Promising results from a saquinavir study.

  TreatmentUpdate 20070101

• Anti-HIV agents. Starting therapy with saquinavir.

  TreatmentUpdate 20070101

• Food consumption, cytochrome P450 3A4 (CYP3A4) presystemic inhibitors, and bioavailability of saquinavir.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

• Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

  Antiviral therapy 20070101

• Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.

  Antiviral therapy 20070101

• First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis.

  Clinical drug investigation 20070101

• Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20070101

• Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

  Antiviral therapy 20070101

• Better lipid profile for Invirase.

  AIDS patient care and STDs 20061201

• Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.

  Journal of molecular graphics & modelling 20061101

• The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20061101

• Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.

  Research in microbiology 20061101

• Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.

  Pharmaceutical research 20061101

• Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20061101

• Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).

  The Journal of infectious diseases 20061101

• Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20061101

• Saquinavir and rifampicin for tuberculosis and AIDS: new considerations.

  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20061101

• HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice.

  Biomedical chromatography : BMC 20061001

• Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.

  The Journal of pharmacology and experimental therapeutics 20060901

• Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.

  Optometry (St. Louis, Mo.) 20060901

• Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults.

  Pharmacotherapy 20060901

• Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.

  Pharmacotherapy 20060801

• Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.

  Pharmacotherapy 20060801

• Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

  AIDS research and human retroviruses 20060801

• A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model.

  The Journal of pharmacy and pharmacology 20060701

• Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

  HIV medicine 20060701

• Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

  AIDS (London, England) 20060626

• Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model.

  Biophysical journal 20060601

• Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.

  Microbes and infection 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen.

  HIV medicine 20060501

• Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats.

  The Journal of pharmacy and pharmacology 20060501

• The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines.

  Haematologica 20060501

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

  British journal of clinical pharmacology 20060401

• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

  AIDS (London, England) 20060321

• Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

  HIV medicine 20060301

• [Screening of new HIV inhibitors based on the database of traditional Chinese medicine].

  Yao xue xue bao = Acta pharmaceutica Sinica 20060301

• HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.

  Cell death and differentiation 20060201

• Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.

  AIDS (London, England) 20060109

• Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.

  AIDS (London, England) 20060102

• Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet.

  Thrombosis research 20060101

• Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.

  Archives of medical research 20060101

• Saquinavir/Ritonavir: its evolution and current treatment role.

  The AIDS reader 20060101

• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  Basic & clinical pharmacology & toxicology 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART.

  Postepy higieny i medycyny doswiadczalnej (Online) 20060101

• Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery.

  Molecular pharmaceutics 20060101

• A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.

  Rapid communications in mass spectrometry : RCM 20060101

• Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.

  MedGenMed : Medscape general medicine 20060101

• Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.

  Antiviral therapy 20060101

• Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.

  Antiviral therapy 20060101

• Gender: a possible determinant in dosing of dermatologic drugs--an overview.

  Cutaneous and ocular toxicology 20060101

• Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

  HIV clinical trials 20060101

• Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

  Clinical drug investigation 20060101

• Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.

  The Journal of eukaryotic microbiology 20060101

• Drug interactions. Coming soon--a new formulation of saquinavir (Invirase).

  TreatmentUpdate 20060101

• [Development and validation of laboratory methods for antiretroviral quantitation using HPLC].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.

  AIDS (London, England) 20051202

• Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.

  Journal of medical virology 20051201

• No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.

  Therapeutic drug monitoring 20051201

• Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.

  International journal of STD & AIDS 20051201

• Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

  Clinical pharmacology and therapeutics 20051201

• Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.

  European cytokine network 20051201

• Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.

  The Journal of antimicrobial chemotherapy 20051101

• Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359.

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.

  International journal of pharmaceutics 20051013

• Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

  The Pediatric infectious disease journal 20051001

• In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.

  The Journal of pharmacology and experimental therapeutics 20050901

• Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050815

• Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

  European journal of clinical pharmacology 20050801

• Placental transfer of antiretroviral drugs.

  Clinical pharmacology and therapeutics 20050801

• Functional role of P-glycoprotein in the human blood-placental barrier.

  Clinical pharmacology and therapeutics 20050801

• Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis.

  Chemotherapy 20050801

• Potent saquinavir get European nod.

  AIDS patient care and STDs 20050801

• Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.

  Protein science : a publication of the Protein Society 20050701

• Antileishmanial activity of HIV protease inhibitors.

  International journal of antimicrobial agents 20050701

• HIV leucoencephalopathy and TNFalpha expression in neurones.

  Journal of neurology, neurosurgery, and psychiatry 20050701

• FDA notifications. Roche issues letter about saquinavir.

  AIDS alert 20050701

• Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

  AIDS (London, England) 20050520

• Establishment of a biological assay system for human retroviral protease activity.

  Microbes and infection 20050501

• [Current status of HIV protease inhibitors].

  Yao xue xue bao = Acta pharmaceutica Sinica 20050501

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050429

• [A further option in PI therapy. Approval of a new protease inhibitor in the USA].

  MMW Fortschritte der Medizin 20050425

• Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

  The Journal of antimicrobial chemotherapy 20050401

• Involvement of HIV-1 protease in virus-induced cell killing.

  Antiviral research 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Roche issues drug interaction warning.

  AIDS alert 20050401

• Atazanavir affects saquinavir.

  AIDS patient care and STDs 20050401

• P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

  The Journal of pharmacology and experimental therapeutics 20050301

• The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

  HIV medicine 20050301

• Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations.

  Biophysical journal 20050201

• New drugs and dosage forms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050201

• Pill burden reduced for saquinavir.

  AIDS patient care and STDs 20050201

• Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection.

  AIDS (London, England) 20050128

• Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

  British journal of clinical pharmacology 20050101

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.

  International journal of immunopathology and pharmacology 20050101

• Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.

  Journal of chemical information and modeling 20050101

• The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.

  Antiviral therapy 20050101

• Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

  HIV clinical trials 20050101

• Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

  HIV clinical trials 20050101

• The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.

  Antiviral therapy 20050101

• A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

  Antiviral therapy 20050101

• A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.

  Antiviral therapy 20050101

• Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20050101

• Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.

  Antiviral therapy 20050101

• [New formulation--fewer tablets--optimal effect].

  Krankenpflege Journal 20050101

• Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strains.

  Pharmacological research 20041201

• Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

  British journal of pharmacology 20041201

• Antiretrovirals as antimalarial agents.

  The Journal of infectious diseases 20041201

• Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells.

  Oncology reports 20041201

• Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

  The Journal of endocrinology 20041201

• The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.

  Antiviral therapy 20041201

• Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.

  Antiviral therapy 20041201

• Determination of saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography and the analytical error function.

  Journal of pharmaceutical and biomedical analysis 20041119

• International AIDS Conference: compliance issues.

  AIDS (London, England) 20041119

• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

  AIDS (London, England) 20041119

• Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.

  Biochemistry 20041116

• Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.

  Proteins 20041101

• Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20041101

• The effectiveness of highly active antiretroviral therapy in HIV-infected patients.

  Danish medical bulletin 20041101

• Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.

  The Journal of antimicrobial chemotherapy 20041001

• Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

  British journal of clinical pharmacology 20041001

• Miniature device for aqueous and non-aqueous solubility measurements during drug discovery.

  Pharmaceutical research 20041001

• Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.

  Pharmaceutical research 20041001

• The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

  American journal of obstetrics and gynecology 20040801

• Electronic transduction of HIV-1 drug resistance in AIDS patients.

  Chembiochem : a European journal of chemical biology 20040705

• Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.

  The Journal of pharmacology and experimental therapeutics 20040701

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

  Journal of clinical pharmacology 20040701

• Atazanavir: a new protease inhibitor to treat HIV infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701

• Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

  AIDS (London, England) 20040618

• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

  Antiviral therapy 20040601

• Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

  Antiviral therapy 20040601

• Multidrug resistance protein 1-mediated transport of saquinavir by microglia.

  Neuroreport 20040519

• Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.

  Pharmacotherapy 20040501

• Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.

  Pharmaceutical research 20040501

• Practical aspects of transporter model systems: a case study involving SQV.

  Drug metabolism reviews 20040501

• [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].

  MMW Fortschritte der Medizin 20040426

• [FPV plus SQV plus a mini-dose ritonavir. 'Double boosting with compatible partners].

  MMW Fortschritte der Medizin 20040426

• Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

  The Journal of infectious diseases 20040401

• Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).

  Antiviral therapy 20040401

• P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line.

  The new microbiologica 20040401

• Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

  The Journal of infectious diseases 20040315

• Optimizing dosing strategies for the combination of atazanavir plus saquinavir.

  AIDS (London, England) 20040305

• Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.

  The Journal of pharmacology and experimental therapeutics 20040301

• Protease inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN.

  Kidney international 20040301

• The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.

  Journal of clinical pharmacology 20040301

• Oral contraception does not alter single dose saquinavir pharmacokinetics in women.

  British journal of clinical pharmacology 20040301

• Combo approved for HIV treatment.

  The Nurse practitioner 20040301

• In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.

  Pharmaceutical research 20040301

• Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model.

  Pharmaceutical research 20040301

• Boosted saquinavir approved.

  AIDS patient care and STDs 20040301

• Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.

  International journal of antimicrobial agents 20040301

• Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

  AIDS (London, England) 20040220

• Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.

  Organic & biomolecular chemistry 20040207

• Toward the development of a structurally novel class of chiral auxiliaries. Conformational properties of the aldol adducts of oxadiazinones: observation of unusual shielding effects.

  The Journal of organic chemistry 20040206

• Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.

  Antimicrobial agents and chemotherapy 20040201

• Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.

  Biological & pharmaceutical bulletin 20040201

• Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.

  Molecular pharmaceutics 20040112

• Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals.

  The new microbiologica 20040101

• A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.

  American journal of therapeutics 20040101

• FDA approves SQV/r.

  IAPAC monthly 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis.

  Cardiovascular toxicology 20040101

• Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction.

  Clinical pharmacokinetics 20040101

• Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.

  Bioconjugate chemistry 20040101

• Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.

  TreatmentUpdate 20040101

• Anti-HIV agents. No interaction between tenofovir and saquinavir.

  TreatmentUpdate 20040101

• Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.

  TreatmentUpdate 20040101

• Anti-HIV agents. Saquinavir with fosamprenavir.

  TreatmentUpdate 20040101

• Anti-HIV agents. Atazanavir and saquinavir.

  TreatmentUpdate 20040101

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031201

• Stability of extemporaneously prepared saquinavir formulations.

  Journal of clinical pharmacy and therapeutics 20031201

• Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20031201

• A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20031201

• Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.

  Biopharmaceutics & drug disposition 20031101

• Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.

  British journal of clinical pharmacology 20031101

• [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].

  Medicina clinica 20031025

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.

  AIDS (London, England) 20031017

• The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1.

  Journal of pharmaceutical sciences 20031001

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031001

• Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.

  HIV medicine 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

  The Journal of infectious diseases 20030901

• The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.

  The Journal of endocrinology 20030901

• Contraindicated antiretroviral drug combinations.

  New Jersey medicine : the journal of the Medical Society of New Jersey 20030901

• Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.

  Leukemia & lymphoma 20030901

• Boosted PIs: competition hots up.

  The AIDS reader 20030901

• Virological rebound after suppression on highly active antiretroviral therapy.

  AIDS (London, England) 20030815

• Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.

  AIDS (London, England) 20030725

• Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors.

  Journal of immunology (Baltimore, Md. : 1950) 20030615

• A review of low-dose ritonavir in protease inhibitor combination therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030615

• Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.

  AIDS (London, England) 20030613

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20030601

• Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.

  Antiviral therapy 20030601

• Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.

  Chemotherapy 20030501

• Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

  Clinical pharmacology and therapeutics 20030501

• Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.

  AIDS patient care and STDs 20030501

• ['Double boosting' passes the test. LPV/r plus SQV in complicated salvage situation].

  MMW Fortschritte der Medizin 20030428

• Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030401

• Sildenafil does not alter nelfinavir pharmacokinetics.

  Therapeutic drug monitoring 20030401

• Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.

  HIV medicine 20030401

• Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.

  Medical mycology 20030401

• Control of human immunodeficiency virus type-1 protease activity in insect cells expressing Gag-Pol rescues assembly of immature but not mature virus-like particles.

  Virology 20030330

• Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.

  Journal of medical microbiology 20030301

• Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease.

  Biochemistry 20030211

• Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

  The Journal of pharmacology and experimental therapeutics 20030201

• Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20030201

• Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.

  Biological & pharmaceutical bulletin 20030201

• Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.

  Antiviral therapy 20030201

• [HIV protease inhibitors for the treatment of Kaposi's sarcoma].

  Recenti progressi in medicina 20030201

• A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

  Biochemistry 20030128

• Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.

  European journal of medical research 20030128

• Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.

  AIDS (London, England) 20030103

• Predicting HIV drug resistance with neural networks.

  Bioinformatics (Oxford, England) 20030101

• The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling.

  Journal of lipid research 20030101

• Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High performance liquid chromatography.

  Biomedical chromatography : BMC 20030101

• Saquinavir: a review of its use in boosted regimens for treating HIV infection.

  Drugs 20030101

• Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.

  HIV clinical trials 20030101

• Saquinavir/low-dose ritonavir: its use in HIV infection.

  AIDS reviews 20030101

• Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome?

  Scandinavian journal of infectious diseases 20030101

• Diurnal variation of plasma protease inhibitor concentrations.

  AIDS (London, England) 20021206

• Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• Pharmacokinetics of saquinavir co-administered with cimetidine.

  The Journal of antimicrobial chemotherapy 20021201

• Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

  AIDS (London, England) 20021122

• Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021115

• Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

  Diabetes 20021101

• Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

  Journal of clinical microbiology 20021101

• Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.

  Pharmaceutical research 20021101

• Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20021015

• P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.

  The Journal of antimicrobial chemotherapy 20021001

• Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy.

  The Journal of rheumatology 20021001

• Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

  HIV medicine 20021001

• Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.

  HIV medicine 20021001

• Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.

  HIV medicine 20021001

• Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

  AIDS (London, England) 20020927

• The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.

  Cancer research 20020915

• Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

  The Journal of infectious diseases 20020901

• [Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report].

  Archivos de la Sociedad Espanola de Oftalmologia 20020901

• The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

  British journal of clinical pharmacology 20020901

• Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.

  Antiviral therapy 20020901

• Predictors of treatment failure during highly active antiretroviral therapy (racing trial).

  European journal of medical research 20020830

• Garlic supplements and saquinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020801

• Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission.

  Journal of acquired immune deficiency syndromes (1999) 20020801

• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

  Clinical pharmacology and therapeutics 20020801

• Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.

  British journal of clinical pharmacology 20020801

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

  Biochemistry 20020709

• Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.

  Proteins 20020701

• Pharmacokinetics of saquinavir in children during long term treatment.

  The Pediatric infectious disease journal 20020701

• Garlic supplements can impede HIV medication.

  AIDS (London, England) 20020614

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

  British journal of clinical pharmacology 20020601

• Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast.

  Pharmacy world & science : PWS 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• A neutravidin-based assay for reverse transcriptase suitable for high throughput screening of retroviral activity.

  Journal of biochemistry and molecular biology 20020531

• [When nucleoside analogs cannot be tolerated. HIV therapy with booster].

  MMW Fortschritte der Medizin 20020509

• Inhibition of morphine-potentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2-5A(N6B).

  Journal of acquired immune deficiency syndromes (1999) 20020501

• Male sexual dysfunction associated with antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020501

• A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020501

• Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• [More transparency facilities drug choice in general practice. Booster regimens in direct comparison].

  MMW Fortschritte der Medizin 20020409

• Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease.

  Antiviral research 20020401

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.

  HIV medicine 20020401

• Long-term maintenance antiretroviral therapy with saquinavir hard gel, after voluntary abandonment of successful induction HAART.

  Journal of chemotherapy (Florence, Italy) 20020401

• The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

  AIDS (London, England) 20020329

• Eruptive angiolipomas associated with antiretroviral therapy.

  AIDS (London, England) 20020329

• Garlic supplements and HIV medication.

  American family physician 20020315

• Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles.

  Virology 20020315

• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

  AIDS (London, England) 20020308

• Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors.

  AIDS (London, England) 20020308

• [Acute coronary syndromes in patients treated with HIV protease inhibitors].

  Presse medicale (Paris, France : 1983) 20020302

• HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.

  Nature medicine 20020301

• Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

  Clinical pharmacology and therapeutics 20020301

• Development of a chromatographic method for the determination of saquinavir in plasma samples of HIV patients.

  Biomedical chromatography : BMC 20020201

• In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

  The Journal of pharmacy and pharmacology 20020201

• Garlic supplements can impede HIV medication.

  Journal of the American College of Surgeons 20020201

• Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.

  British journal of clinical pharmacology 20020201

• NIH studies link between saquinavir and garlic pills.

  AIDS alert 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.

  AIDS (London, England) 20020125

• Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

  AIDS (London, England) 20020125

• The effect of garlic supplements on the pharmacokinetics of saquinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020115

• Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020115

• Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.

  AIDS (London, England) 20020104

• The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes.

  The Journal of endocrinology 20020101

• CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 20020101

• A SOFM approach to predicting HIV drug resistance.

  Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20020101

• The effect of HAART on humoral immune response in primary HIV-1 infected patients.

  Journal of biological regulators and homeostatic agents 20020101

• Saquinavir with low-dose ritonavir twice daily.

  TreatmentUpdate 20020101

• Invirase vs. Fortovase: unexpected results?

  TreatmentUpdate 20020101

• Saquinavir once daily.

  TreatmentUpdate 20020101

• Could cimetidine be used as a booster?

  TreatmentUpdate 20020101

• Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.

  Antiviral chemistry & chemotherapy 20020101

• Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

  The Body positive 20020101

• Aphtous stomatitis in a patient with Behçet's disease and HIV was associated with an increased HIV load.

  Clinical and experimental rheumatology 20020101

• Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.

  HIV clinical trials 20020101

• Garlic reduces saquinavir blood levels 50%; may affect other drugs.

  AIDS treatment news 20011221

• Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy?

  European psychiatry : the journal of the Association of European Psychiatrists 20011201

• Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).

  Antiviral therapy 20011201

• Drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20011126

• HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells.

  AIDS (London, England) 20011123

• Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.

  Carbohydrate research 20011121

• Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

  The Journal of infectious diseases 20011115

• Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.

  AIDS (London, England) 20011109

• Effects of the membrane dipole potential on the interaction of saquinavir with phospholipid membranes and plasma membrane receptors of Caco-2 cells.

  The Journal of biological chemistry 20011019

• HIV-1 induction-maintenance at the lymph node level: the 'Apollo-97' Study.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• [Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001].

  Presse medicale (Paris, France : 1983) 20010922

• Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

  Archives of internal medicine 20010910

• Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.

  AIDS (London, England) 20010907

• Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.

  The Journal of antimicrobial chemotherapy 20010901

• Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

  British journal of clinical pharmacology 20010901

• Searching for the right dose of ritonavir-saquinavir.

  TreatmentUpdate 20010901

• Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.

  Journal of neuroimmunology 20010830

• Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells.

  Life sciences 20010817

• Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

  Blood 20010815

• HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.

  Therapeutic drug monitoring 20010801

• Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.

  Therapeutic drug monitoring 20010801

• A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.

  Clinical pharmacology and therapeutics 20010801

• Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28.

  Journal of chemotherapy (Florence, Italy) 20010801

• P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  AIDS (London, England) 20010727

• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

  The British journal of ophthalmology 20010701

• Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20010701

• HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.

  FEMS immunology and medical microbiology 20010701

• Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model.

  American journal of obstetrics and gynecology 20010701

• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010615

• Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.

  AIDS research and human retroviruses 20010610

• Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.

  The Journal of organic chemistry 20010601

• Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.

  British journal of clinical pharmacology 20010601

• The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.

  Journal of the American Dietetic Association 20010601

• Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.

  Antiviral therapy 20010601

• Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.

  AIDS (London, England) 20010525

• Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir.

  International journal of pharmaceutics 20010507

• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

  AIDS (London, England) 20010504

• The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients.

  European journal of clinical pharmacology 20010501

• [HIV-HBV coinfection and the liver].

  Gastroenterologie clinique et biologique 20010501

• Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

  Analytical biochemistry 20010415

• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

  AIDS (London, England) 20010413

• Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

  AIDS research and human retroviruses 20010410

• [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].

  MMW Fortschritte der Medizin 20010402

• P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

  Molecular pharmacology 20010401

• Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells.

  The Journal of antimicrobial chemotherapy 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.

  Molecular therapy : the journal of the American Society of Gene Therapy 20010401

• Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

  The Journal of infection 20010401

• Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20010301

• The safety and antiviral effect of protease inhibitors in children.

  Pharmacotherapy 20010301

• Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.

  AIDS patient care and STDs 20010301

• Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy.

  AIDS (London, England) 20010216

• Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

  The Journal of infectious diseases 20010215

• Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20010201

• [Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].

  Annales de medecine interne 20010201

• Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.

  Nephron 20010201

• Pharmacology and clinical experience with saquinavir.

  Expert opinion on pharmacotherapy 20010201

• [Resistance to protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010201

• The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.

  AIDS (London, England) 20010126

• Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

  AIDS research and human retroviruses 20010120

• The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.

  AIDS (London, England) 20010105

• Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

  British journal of clinical pharmacology 20010101

• Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

  Journal of clinical laboratory analysis 20010101

• Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.

  In vivo (Athens, Greece) 20010101

• Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.

  Scandinavian journal of infectious diseases 20010101

• Saquinavir soft gelatin capsule: a comparative safety review.

  Drug safety 20010101

• Garlic supplements found to lower saquinavir levels.

  TreatmentUpdate 20010101

• From grapefruit juice to ritonavir.

  TreatmentUpdate 20010101

• A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.

  HIV clinical trials 20010101

• The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

  HIV clinical trials 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.

  HIV clinical trials 20010101

• Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.

  HIV clinical trials 20010101

• MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.

  HIV medicine 20010101

• Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.

  HIV medicine 20010101

• Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.

  HIV medicine 20010101

• Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

  HIV clinical trials 20010101

• Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.

  HIV clinical trials 20010101

• Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.

  Journal of virology 20000801

• Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

  Antiviral chemistry & chemotherapy 20000701

• In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

  The Journal of infectious diseases 20000501

• Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir.

  Antiviral chemistry & chemotherapy 20000301

• Decreased methadone effect after ritonavir initiation.

  Pharmacotherapy 20000101

• Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.

  The American journal of medicine 19991201

• Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.

  Archiv der Pharmazie 19991101

• Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor.

  AIDS (London, England) 19991001

• The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance.

  AIDS research and human retroviruses 19990301

• Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.

  Antimicrobial agents and chemotherapy 19990201

• Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.

  Archiv der Pharmazie 19990101

• Lipid lowering therapy in patients with HIV infection.

  Lancet (London, England) 19981128

• [Nephrotoxicity of ritonavir].

  Presse medicale (Paris, France : 1983) 19981114

• In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

  Journal of virology 19980901

• Renal calculi developing de novo in a patient taking saquinavir.

  International journal of STD & AIDS 19980901

• New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.

  Journal of medicinal chemistry 19980827

• Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

  The Journal of infectious diseases 19980801

• Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

  Bioorganic & medicinal chemistry letters 19980317

• Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.

  Biochemistry 19971007

• Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir.

  The Journal of antimicrobial chemotherapy 19970601

• In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.

  The Journal of infectious diseases 19970501

• Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

  Biochimica et biophysica acta 19970425

• Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 19970201

• Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

  Proceedings of the National Academy of Sciences of the United States of America 19960220

• Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.

  Antimicrobial agents and chemotherapy 19960201

• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.

  Antiviral research 19960101

• Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.

  Antiviral research 19960101

• Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

  Biochemistry 19950725

• Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.

  AIDS research and human retroviruses 19950601

• The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.

  Antiviral research 19950301

• Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

  Virology 19950110

• Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.

  Journal of medicinal chemistry 19940805

• The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.

  Journal of medicinal chemistry 19940415

• Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.

  Antimicrobial agents and chemotherapy 19940201

• Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase.

  Antiviral research 19911201

• The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells.

  Biochemical and biophysical research communications 19910415